Jamjoom Pharma, one of the fastest-growing pharmaceutical companies in Saudi Arabia and across MEA, has announced the signing of a Memorandum of Understanding (MoU) with Caritas Egypt, aimed at launching a comprehensive national initiative for early detection of ocular surface disorders and raising health awareness among the most vulnerable groups.
This partnership comes in line with Egypt Vision 2030 and the presidential public health initiatives, as Jamjoom Pharma seeks through it to leverage its technical and medical expertise to serve Egyptian society.
Under this agreement, signed by Dr Ali Yehia, General Manager and Cluster Head of Jamjoom Pharma in Egypt and North Africa, and Dr Ayman Sadek, General Director of Caritas Egypt, both parties will work to organise a series of early screening campaigns across the association’s branches nationwide. The first phase is scheduled to launch from six main branches in Cairo and Giza governorates, with an ambitious expansion plan to include Alexandria, the Delta, and Upper Egypt.
"This collaboration opens new horizons for integrated development work, as the three-month pilot phase will help establish a precise roadmap for future geographical expansion", said Dr Ayman Sadek, General Director of Caritas Egypt.
Dr Ali Yehia, General Manager and Cluster Head of Jamjoom Pharma in Egypt and North Africa said, "This initiative is fully aligned with the Egyptian state’s strategic direction to enhance the quality of life for citizens and localize innovative treatment solutions. We aim, by harnessing our scientific resources and providing medical samples and awareness materials, to build a community with strong visual health, which directly contributes to productivity rates and sustainable development aspired to by the New Republic”
